Featured Publications
Cumulative live birth rates with autologous oocytes plateau with fewer number of cycles for each year of age > 42
Seifer D, Wang S, Frankfurter D. Cumulative live birth rates with autologous oocytes plateau with fewer number of cycles for each year of age > 42. Reproductive Biology And Endocrinology 2023, 21: 94. PMID: 37872609, PMCID: PMC10591412, DOI: 10.1186/s12958-023-01144-z.Peer-Reviewed Original ResearchConceptsCumulative live birth rateLive birth rateART cyclesBirth rateDesignRetrospective cohort studyPrior ART cyclesUse of ICSIEtiology of infertilityNumber of oocytesAge categoriesSART CORS databaseYears of ageTreatment cycle numberRace/ethnicityAutologous cyclesResultsBetween 2014Ovarian reserveCohort studyBlastocyst transferWomen 46Women 42Age 45Live birthsMAIN OUTCOMEPhysician expectations
2024
Assessment of a Decade of Change in U.S. Assisted Reproductive Technology Cumulative Live-Birth Rates
Wang S, Seifer D. Assessment of a Decade of Change in U.S. Assisted Reproductive Technology Cumulative Live-Birth Rates. Obstetrics And Gynecology 2024, 143: 839-848. PMID: 38696814, DOI: 10.1097/aog.0000000000005598.Peer-Reviewed Original ResearchConceptsCumulative live birth rateLive birth rateAssisted reproductive technologyPreimplantation genetic testingInfertility diagnosisLive birthsOvulatory disordersGenetic testingReproductive technologyOdds of live birthMale factor infertilityFrozen embryo transferDiminished ovarian reserveClinical practiceRetrospective cohort studyAssociated with decreased oddsSART CORS databaseField of assisted reproductive technologyDemographic shiftsSART CORSOvarian reserveInfertility causeEmbryo transferCounseling patientsCohort study
2022
State insurance mandates for in vitro fertilization are not associated with improving racial and ethnic disparities in utilization and treatment outcomes
Correia K, Kraschel K, Seifer D. State insurance mandates for in vitro fertilization are not associated with improving racial and ethnic disparities in utilization and treatment outcomes. American Journal Of Obstetrics And Gynecology 2022, 228: 313.e1-313.e8. PMID: 36356698, DOI: 10.1016/j.ajog.2022.10.043.Peer-Reviewed Original ResearchConceptsNon-Hispanic white womenClinical outcomesEthnic disparitiesFertilization cyclesFertility careAssisted Reproductive Technology Clinical Outcomes Reporting SystemBlack/African American womenWhite womenSingle stimulation cycleInsurance mandatesReproductive-aged womenRecent study yearsLack of insuranceAfrican American womenAutologous cyclesLiveborn neonatesCohort studyPrimary outcomeState insurance mandatesState health insurance mandatesStimulation cyclesTreatment outcomesWomenHealth insurance mandatesOutcomesA Bedside Test to Detect the Presence of Embryonic or Fetal Tissue in Vaginal Blood
Volovsky M, Ayala M, Narayanamoorthy S, Chiware T, Kotlyar A, Taylor H, Seifer D, Mor A. A Bedside Test to Detect the Presence of Embryonic or Fetal Tissue in Vaginal Blood. Obstetrics And Gynecology 2022, 140: 983-988. PMID: 36357961, DOI: 10.1097/aog.0000000000004975.Peer-Reviewed Original ResearchConceptsVaginal bloodEctopic pregnancyPositive control groupAlpha-fetoproteinControl groupFetal tissuesNegative control groupComplete miscarriageIGFBP-1Bedside testStudy groupInsulin-like growth factor-binding protein-1Growth factor-binding protein-1First-trimester bleedingProspective cohort studyRapid bedside testIntrauterine pregnancyVaginal bleedingCohort studyNonpregnant individualsReproductive-aged individualsPregnant individualsRapid test stripPregnancyMiscarriage
2021
Miscarriage determination in first trimester based on alpha-fetoprotein extracted from sanitary pads
Mor A, Gardezi M, Jubanyik K, Simsek B, Seifer DB, Patrizio P, Esencan E, Imamoglu G, Zhang M, Nichols-Burns SM, Taylor HS. Miscarriage determination in first trimester based on alpha-fetoprotein extracted from sanitary pads. Fertility And Sterility 2021, 116: 462-469. PMID: 33461753, DOI: 10.1016/j.fertnstert.2020.10.006.Peer-Reviewed Original ResearchConceptsExtrauterine pregnancyVaginal bloodAlpha-fetoproteinOngoing pregnancyAFP levelsSanitary padsHigh alpha-fetoprotein levelsOngoing pregnancy groupProspective cohort studyAlpha-fetoprotein levelsAcademic medical centerPregnancy groupCohort studyMiscarriage casesFirst trimesterOffice visitsMedical CenterMAIN OUTCOMEPregnancyMedian levelsMiscarriageBloodAnxiety levelsAFPCharacteristic analysis
2020
Do state insurance mandates alter ICSI utilization?
Zagadailov P, Seifer DB, Shan H, Zarek SM, Hsu AL. Do state insurance mandates alter ICSI utilization? Reproductive Biology And Endocrinology 2020, 18: 33. PMID: 32334609, PMCID: PMC7183130, DOI: 10.1186/s12958-020-00589-w.Peer-Reviewed Original ResearchConceptsIntracytoplasmic sperm injectionElective single embryo transferClinical pregnancyICSI usePreimplantation genetic testingESET rateState insurance mandatesTwin rateInsurance mandatesRetrospective cohort studyLive birth rateLower clinical pregnancyMale factor infertilitySingle embryo transferBirth rateTwin birth rateT-testICSI rateLower LBRStrength of associationCohort studyFactor infertilityART cyclesResultsFrom 2000ART coverage
2018
Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility
Butts SF, Seifer DB, Koelper N, Senapati S, Sammel MD, Hoofnagle AN, Kelly A, Krawetz SA, Santoro N, Zhang H, Diamond MP, Legro RS, Network E. Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility. The Journal Of Clinical Endocrinology & Metabolism 2018, 104: 369-378. PMID: 30085176, PMCID: PMC6300410, DOI: 10.1210/jc.2018-00750.Peer-Reviewed Original ResearchConceptsVitamin D deficiencyPolycystic ovary syndromeD deficiencyEarly pregnancy lossOvarian stimulationUnexplained infertilityLive birthsPregnancy lossDiagnosis of PCOSMultiple Intrauterine GestationsOvarian stimulation outcomesRetrospective cohort studyInvestigation of womenBanked seraPPCOS IICohort studyIntrauterine gestationOvary syndromeInfertile womenInfertility diagnosisPregnant subjectsElevated riskImportant treatmentReproductive outcomesTrial dataTemporal Differences in Utilization of Intracytoplasmic Sperm Injection Among U.S. Regions
Zagadailov P, Hsu A, Stern JE, Seifer DB. Temporal Differences in Utilization of Intracytoplasmic Sperm Injection Among U.S. Regions. Obstetrics And Gynecology 2018, 132: 310-320. PMID: 29995722, DOI: 10.1097/aog.0000000000002730.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsCohort StudiesFemaleFertilization in VitroHumansInfertility, FemaleInfertility, MaleLive BirthMalePregnancyPregnancy RateRetrospective StudiesSperm Injections, IntracytoplasmicTreatment OutcomeUnited StatesUnited States Dept. of Health and Human ServicesYoung AdultConceptsLive birth rateUse of ICSIICSI rateICSI utilizationBirth rateRetrospective cohort studyMale factor infertilityHuman Services (HHS) regionsIntracytoplasmic sperm injectionYears of agePreimplantation genetic testingMale factor diagnosisDepartment of HealthNondonor cyclesCohort studyFertilization cyclesFactor infertilityMale factorSperm injectionMedical indicationsMagnitude of increaseClinicGenetic testingDisease controlICSI
2015
Alpha-Fetoprotein as a Tool to Distinguish Amniotic Fluid From Urine, Vaginal Discharge, and Semen
Mor A, Tal R, Haberman S, McCalla S, Irani M, Perlman J, Seifer DB, Minkoff H. Alpha-Fetoprotein as a Tool to Distinguish Amniotic Fluid From Urine, Vaginal Discharge, and Semen. Obstetrics And Gynecology 2015, 125: 448-452. PMID: 25569004, DOI: 10.1097/aog.0000000000000635.Peer-Reviewed Original ResearchConceptsNormal vaginal dischargeAlpha-fetoprotein concentrationDiagnosis of ruptureVaginal dischargeAmniotic fluidAlpha-fetoproteinPregnant womenReceiver operator characteristic curve analysisSanitary padsOperator characteristic curve analysisProspective cohort studyAlpha-fetoprotein levelsAmniotic fluid levelsCharacteristic curve analysisAmniotic fluid specimensCohort studyInfertility evaluationMaternal urineAFP levelsFluid specimensFluid levelsSemen specimensCurve analysisUrineAFP quantification
2014
Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Follicular fluid placental growth factor is increased in polycystic ovarian syndrome: correlation with ovarian stimulation. Reproductive Biology And Endocrinology 2014, 12: 82. PMID: 25141961, PMCID: PMC4150963, DOI: 10.1186/1477-7827-12-82.Peer-Reviewed Original ResearchMeSH KeywordsAdultCohort StudiesDown-RegulationFamily CharacteristicsFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleInfertility, MaleMaleNew York CityOocyte RetrievalOvarian ReserveOvulation InductionPlacenta Growth FactorPolycystic Ovary SyndromePregnancyPregnancy ProteinsPregnancy RateProspective StudiesUp-RegulationVascular Endothelial Growth Factor Receptor-1ConceptsNon-PCOS controlsPCOS womenOvarian stimulationSFlt-1 levelsAnti-Mullerian hormonePlacental growth factorVascular endothelial growth factorFollicular fluidOvarian syndromeSFlt-1Growth factorSoluble receptor sFlt-1BackgroundPolycystic ovarian syndromeControlled ovarian stimulationPlGF/sFltDay of hCGProspective cohort studyPolycystic ovarian syndromeNumber of oocytesEndothelial growth factorVEGF family membersCohort studyOocyte retrievalPlGF levelsVascular changesAssisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011
Butts SF, Owen C, Mainigi M, Senapati S, Seifer DB, Dokras A. Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011. Fertility And Sterility 2014, 102: 1041-1047.e1. PMID: 25086790, PMCID: PMC4184996, DOI: 10.1016/j.fertnstert.2014.06.043.Peer-Reviewed Original ResearchMeSH KeywordsChi-Square DistributionEmbryo Culture TechniquesEmbryo TransferFemaleHumansInfertility, FemaleLive BirthLogistic ModelsOdds RatioOvarian ReservePregnancyPregnancy RatePrimary Ovarian InsufficiencyRegistriesRetrospective StudiesRisk FactorsSperm Injections, IntracytoplasmicTime FactorsTreatment OutcomeUnited StatesConceptsDiminished ovarian reserveIntracytoplasmic sperm injectionElevated FSHLive birthsOvarian reserveART cyclesSperm injectionAssisted Reproductive Technology Clinic Outcome Reporting System databaseClinical pregnancy rateRetrospective cohort studyLive birth rateReproductive technology outcomesAssisted reproduction cyclesCombination of ICSIReporting System databaseCohort studyPrimary diagnosisImproved outcomesPregnancy rateMAIN OUTCOMELower oddsDiminished oddsFSHOnly indicationTechnology outcomesCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2013
Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation. Vascular Cell 2013, 5: 18. PMID: 24156373, PMCID: PMC3895756, DOI: 10.1186/2045-824x-5-18.Peer-Reviewed Original ResearchPolycystic ovarian syndromeAng-2 levelsAng-1 levelsPCOS womenNumber of oocytesAng-2Ovarian stimulationRetrieval dayAngiopoietin-2Follicular fluidAng-1Angiopoietin-1Serum Ang-1 levelsSerum Ang-2 levelsAng-1/AngSerum Ang-1Prospective cohort studyOvarian hyperstimulationOvarian syndromeCohort studyOvarian functionCapillary leakageFF levelsDay 3Time points
2009
Trends of racial disparities in assisted reproductive technology outcomes in black women compared with white women: Society for Assisted Reproductive Technology 1999 and 2000 vs. 2004–2006
Seifer DB, Zackula R, Grainger DA, Report S. Trends of racial disparities in assisted reproductive technology outcomes in black women compared with white women: Society for Assisted Reproductive Technology 1999 and 2000 vs. 2004–2006. Fertility And Sterility 2009, 93: 626-635. PMID: 19368916, DOI: 10.1016/j.fertnstert.2009.02.084.Peer-Reviewed Original ResearchConceptsWhite womenCycles of IVFPoor prognostic factorReproductive technology outcomesNon-Hispanic womenBlack womenTubal factorIVF cyclesOvulation disordersCohort studyOvarian reserveIVF outcomesPrognostic factorsUterine factorsReporting of raceMale factorLive birthsMAIN OUTCOMEART outcomesMember clinicsOlder ageRacial disparitiesWomenFresh embryosReproductive technologies
2008
Variations in serum müllerian inhibiting substance between white, black, and Hispanic women
Seifer DB, Golub ET, Lambert-Messerlian G, Benning L, Anastos K, Watts DH, Cohen MH, Karim R, Young MA, Minkoff H, Greenblatt RM. Variations in serum müllerian inhibiting substance between white, black, and Hispanic women. Fertility And Sterility 2008, 92: 1674-1678. PMID: 18930217, PMCID: PMC3037722, DOI: 10.1016/j.fertnstert.2008.08.110.Peer-Reviewed Original ResearchConceptsBody mass indexHispanic womenHIV statusMass indexMulticenter prospective cohort studyWomen's Interagency HIV StudySerum MIS levelsProspective cohort studyTime pointsCohort studyDifferent time pointsMIS levelsAge-related declineHIV StudyDifferent time coursesMAIN OUTCOMESubstance levelsSerum MISWhite womenSerum samplesDifferent racial groupsWomenIndependent effectsLongitudinal studySmoking
2007
Disparity in assisted reproductive technologies outcomes in black women compared with white women
Seifer DB, Frazier LM, Grainger DA. Disparity in assisted reproductive technologies outcomes in black women compared with white women. Fertility And Sterility 2007, 90: 1701-1710. PMID: 17980873, DOI: 10.1016/j.fertnstert.2007.08.024.Peer-Reviewed Original ResearchMeSH KeywordsAbortion, SpontaneousAdultBlack or African AmericanFemaleHealth Knowledge, Attitudes, PracticeHealthcare DisparitiesHumansInfertilityLive BirthPatient Acceptance of Health CareRegistriesReproductive Techniques, AssistedRetrospective StudiesRisk FactorsTime FactorsTreatment OutcomeUnited StatesWhite PeopleConceptsLive birth rateIVF cyclesWhite womenAssisted Reproductive Technology member clinicsBlack womenMarried reproductive age womenCycles of IVFIndependent risk factorRetrospective cohort studyReproductive technology outcomesReproductive-age womenUterine factor infertilityRace/ethnicityCohort studyFactor infertilityBlack raceRisk factorsSpontaneous abortionRegistry dataLive birthsMAIN OUTCOMEEmbryo cyclesIVF recipientsMember clinicsWomenBiologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women
Seifer DB, Golub ET, Lambert-Messerlian G, Springer G, Holman S, Moxley M, Cejtin H, Nathwani N, Anastos K, Minkoff H, Greenblatt RM. Biologic markers of ovarian reserve and reproductive aging: application in a cohort study of HIV infection in women. Fertility And Sterility 2007, 88: 1645-1652. PMID: 17418155, PMCID: PMC2682326, DOI: 10.1016/j.fertnstert.2007.01.122.Peer-Reviewed Original ResearchConceptsWomen's Interagency HIV StudyEarly follicular phaseOvarian reserveInhibin BHIV infectionMIS levelsFollicular phaseHIV StudyLower inhibin B levelsReproductive agingSerum samplesHIV infection influencesInhibin B levelsMulticenter prospective studyCross-sectional studyMenstrual cycle phaseCycle phaseUninfected womenCohort studyFSH levelsMenstrual bleedingNegative womenHIV serostatusSerum markersProspective study
2006
Effects of HIV Infection and Its Treatment on Self-Reported Menstrual Abnormalities in Women
Massad LS, Evans CT, Minkoff H, Watts DH, Greenblatt RM, Levine AM, Anastos K, Young M, Seifer DB, Golub E, Cohen M. Effects of HIV Infection and Its Treatment on Self-Reported Menstrual Abnormalities in Women. Journal Of Women's Health 2006, 15: 591-598. PMID: 16796486, DOI: 10.1089/jwh.2006.15.591.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountComorbidityConfidence IntervalsFemaleHIV InfectionsHIV SeronegativityHIV SeropositivityHumansIncidenceMenstruation DisturbancesMulticenter Studies as TopicOdds RatioPrevalenceProspective StudiesRisk FactorsSurveys and QuestionnairesWomen's HealthConceptsHigher CD4 countsHIV-seropositive womenMenstrual abnormalitiesCD4 countHIV serostatusActive anti-retroviral therapy (HAART) useAnti-retroviral therapy useMulticenter prospective cohort studyCox proportional hazards modelProspective cohort studyHIV natural historyProportional hazards modelSeronegative womenHAART useCohort studyHIV infectionTherapy usePrevalent abnormalityMenstrual changesMenstrual problemsMost abnormalitiesNatural historyAbnormalitiesLogistic regressionWomen
2000
Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies.
Phipps M, Hogan J, Peipert J, Lambert-Messerlian G, Canick J, Seifer D. Progesterone, inhibin, and hCG multiple marker strategy to differentiate viable from nonviable pregnancies. Obstetrics And Gynecology 2000, 95: 227-31. PMID: 10674584, DOI: 10.1016/s0029-7844(99)00480-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersChorionic GonadotropinChorionic Gonadotropin, beta Subunit, HumanCohort StudiesFemaleFetal ViabilityHumansInhibinsPredictive Value of TestsPregnancyPregnancy ComplicationsPregnancy OutcomePregnancy Trimester, FirstProgesteroneProspective StudiesROC CurveSensitivity and SpecificityConceptsDual-biomarker strategyMultiple biomarker strategyNonviable pregnanciesSerum progesteroneBiomarker strategiesComplaints of painProspective cohort studySymptomatic pregnant womenCombination of progesteroneCohort studyCombination of serumInhibin AUrine biomarkersFirst trimesterPregnant womenEarly gestationNonviable outcomesPregnancySingle biomarkerHCGProgesteroneSpecific biomarkersDiagnostic accuracySerum samplesBiomarkersProgesterone, Inhibin, and hCG Multiple Marker Strategy to Differentiate Viable From Nonviable Pregnancies
PHIPPS M, HOGAN J, PEIPERT J, LAMBERT-MESSERLIAN G, CANICK J, SEIFER D. Progesterone, Inhibin, and hCG Multiple Marker Strategy to Differentiate Viable From Nonviable Pregnancies. Obstetrics And Gynecology 2000, 95: 227-231. DOI: 10.1097/00006250-200002000-00011.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersChorionic GonadotropinChorionic Gonadotropin, beta Subunit, HumanCohort StudiesFemaleFetal ViabilityHumansInhibinsPredictive Value of TestsPregnancyPregnancy ComplicationsPregnancy OutcomePregnancy Trimester, FirstProgesteroneProspective StudiesROC CurveSensitivity and SpecificityConceptsDual-biomarker strategyMultiple biomarker strategyNonviable pregnanciesSerum progesteroneBiomarker strategiesComplaints of painProspective cohort studySymptomatic pregnant womenCombination of progesteroneCohort studyCombination of serumInhibin AUrine biomarkersFirst trimesterPregnant womenEarly gestationNonviable outcomesPregnancySingle biomarkerHCGProgesteroneSpecific biomarkersDiagnostic accuracySerum samplesBiomarkers